Share This Profile
Share this profile on Facebook.
Link to this profile on LinkedIn.
Tweet this profile on Twitter.
Email a link to this profile.
See other services through which you can share this profile.
This profile was last updated on 1/28/16  and contains information from public web pages and contributions from the ZoomInfo community.

Mr. Mark Taylor

Wrong Mark Taylor?

Senior Executive

Hallux Inc
Phone: (949) ***-****  
Local Address:  Laguna Hills , California , United States
Hallux Consulting Inc
440 Laurier Avenue West
Ottawa , Ontario K1R 7X6

Company Description: Hallux Consulting Inc. is a Canadian corporation that has been providing a broad range of high quality audit and review services and consulting expertise since...   more

Employment History

Board Memberships and Affiliations

  • Board Member
    Medical Care Corporation


  • Bachelor of Science degree
    Tulane University
82 Total References
Web References
Mark ..., 28 Jan 2016 [cached]
Mark Taylor
Mark Taylor has over 20 years in the specialty pharmaceuticals sector serving as a senior executive of several public companies, and as a sell-side pharmaceutical analyst.
Most recently, Mr. Taylor was Senior Vice President of Corporate Development for Obagi Medical Products Inc., the market share leader in physician-dispensed dermatologics. Valeant Pharmaceuticals International acquired Obagi in April 2013.
Prior to Obagi, Mr. Taylor was Vice President, Diagnostics for MP Biomedicals, LLC, a privately held global provider of infectious disease screening and confirmatory tests.
Mr. Taylor also served Roth Capital Partners for five years where he held the titles of Managing Director of Healthcare Banking and Senior Pharmaceutical Analyst.
Prior to Roth, Mr. Taylor was head of the largest division at ICN Pharmaceuticals Inc. (now Valeant Pharmaceuticals International) as Executive Vice President, North America. Under Mr. Taylor's leadership, ICN expanded its dermatology division by adding prescription products, physician dispensed skin care brands, and light activated devices to its portfolio.
Mr. Taylor also served as Vice President of Business Development at Watson Pharmaceuticals (now Allergan plc.), another large dermatology products provider. During this time Watson made its first foray into dermatology products by acquiring Oclassen Pharmaceuticals, Inc.
Mark is a graduate of Tulane University and serves on the board of Medical Care Corporation, a private company focused on Alzheimer's research and diagnosis.
Cholesterol Drugs Pharmaceuticals Drugmakers Niaspan Asthma Diabetes Abbot Drugs, 18 Dec 2006 [cached]
"This was a company that was primed to be taken out," said Mark Taylor, a senior pharmaceuticals analyst at Roth Capital Partners.
Roth Capital Partners, 17 Nov 2008 [cached]
Mark Taylor Managing Director, Newport Beach 949-720-5728
Roth Capital Partners, 16 Oct 2008 [cached]
Mark Taylor, Managing Director
t: 949-720-5728, e:
Mark Taylor is a Managing Director in the investment banking department with an emphasis in Healthcare and specializing in Pharmaceuticals. From 2003-2007, Mark was a Senior Research Analyst at ROTH covering the specialty pharmaceuticals sector. In that capacity, he initiated coverage on 24 companies and was twice named by the Wall Street Journal to their prestigious "Best on the Street" annual ranking of analysts for stock picking performance in a respective category. Prior to joining ROTH, Mr. Taylor held various executive positions within industry. From 1999-2002, Mr. Taylor was an executive at ICN Pharmaceuticals Inc. holding the positions of Vice President Corporate Development and Executive Vice President in charge of North American Pharmaceuticals. From 1997-1999, Mr. Taylor was Vice President of Business Development for Watson Pharmaceuticals Inc., a leading brand and generic drug company. From 1994-1997, Mr. Taylor was a Vice President at SPI Pharmaceuticals Inc., a branded drug company. From 1986-1994, Mr. Taylor specialized in biotechnology and health care as a retail and institutional salesman at such firms as Lehman Brothers, and Alex Brown & Sons. Mr. Taylor received a Bachelor of Science degree from Tulane University in 1980.
Mark Taylor, 2 April 2007 [cached]
Mark Taylor, Senior Research Analyst
Mark Taylor is a Senior Research Analyst covering small - mid tier pharmaceuticals for Roth Capital Partners.In 2005, the North American Analyst Survey ranked Mr. Taylor #1 Stock Picker in the Pharmaceuticals sector.In the same year, the Wall Street Journal's "Best on the Street Analysts Survey" ranked Mr. Taylor as the #2 stock picker in the pharmaceuticals category.
Prior to joining Roth, Mr. Taylor held various executive positions within the pharmaceuticals industry.From 1999-2002, Mr. Taylor was Executive Vice President North American Pharmaceuticals for ICN Pharmaceuticals Inc., a NYSE global pharma company.From 1997-1999, Mr. Taylor was Vice President of Business Development for Watson Pharmaceuticals Inc., a leading NYSE brand and generic drug leader.From 1994-1997, Mr. Taylor was employed by SPI Pharmaceuticals Inc. in various corporate development positions.From 1986-1994, Mr. Taylor specialized in biotechnology and health care as a retail and institutional salesman at Lehman Brothers, and Alex Brown & Sons.Mr. Taylor received a Bachelor of Science degree from Tulane University in 1980.
Other People with the name "Taylor":
Other ZoomInfo Searches
Accelerate your business with the industry's most comprehensive profiles on business people and companies.
Find business contacts by city, industry and title. Our B2B directory has just-verified and in-depth profiles, plus the market's top tools for searching, targeting and tracking.
Atlanta | Boston | Chicago | Houston | Los Angeles | New York
Browse ZoomInfo's business people directory. Our professional profiles include verified contact information, biography, work history, affiliations and more.
Browse ZoomInfo's company directory. Our company profiles include corporate background information, detailed descriptions, and links to comprehensive employee profiles with verified contact information.